{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T05:06:36Z","timestamp":1704517596065},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,1,1]]},"DOI":"10.2169\/internalmedicine.1040-22","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T02:31:41Z","timestamp":1683685901000},"page":"125-130","source":"Crossref","is-referenced-by-count":0,"title":["Antineutrophil Cytoplasmic Autoantibody-negative Pauci-immune Necrotizing Glomerulonephritis with Plasma Cell-rich Tubulointerstitial Nephritis Complicated with Pleuritis and Digital Ischemia"],"prefix":"10.2169","volume":"63","author":[{"given":"Taito","family":"Miyake","sequence":"first","affiliation":[{"name":"Department of Nephrology and Rheumatology, Koseiren Takaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Sanada","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Koseiren Takaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamano","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Koseiren Takaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Koseiren Takaoka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65: 1-11, 2013.","DOI":"10.1007\/s10157-013-0869-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Rhee RL, Hogan SL, Poulton CJ, et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol 68: 1711-1720, 2016.","DOI":"10.1002\/art.39614"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232, 2010.","DOI":"10.1056\/NEJMoa0909905"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Charles P, Perrodeau \u00c9, Samson M, et al.; the French Vasculitis Study Group. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 173: 179-187, 2020.","DOI":"10.7326\/L20-1199"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis 76: 647-653, 2017.","DOI":"10.1136\/annrheumdis-2016-209507"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nakazawa D, Masuda S, Tomaru U, et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15: 91-101, 2019.","DOI":"10.1038\/s41584-018-0145-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hagen EC, Daha MR, Hermans J, et al.; the EC\/BCR Project for ANCA Assay Standardization. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 53: 743-753, 1998.","DOI":"10.1046\/j.1523-1755.1998.00807.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66: 222-227, 2007.","DOI":"10.1136\/ard.2006.054593"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 123: 1773-1783, 2013.","DOI":"10.1172\/JCI65292"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13: 683-692, 2017.","DOI":"10.1038\/nrrheum.2017.140"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220, 2010.","DOI":"10.1056\/NEJMoa0909169"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 26: 976-985, 2015.","DOI":"10.1681\/ASN.2014010046"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371: 1771-1780, 2014.","DOI":"10.1056\/NEJMoa1404231"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382: 622-631, 2020.","DOI":"10.1056\/NEJMoa1803537"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA 325: 2178-2187, 2021.","DOI":"10.1001\/jama.2021.13879"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chen M, Yu F, Wang SX, et al. Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol 18: 599-605, 2007.","DOI":"10.1681\/ASN.2006091021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Danlos FX, Rossi GM, Blockmans D, et al. Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: a new overlap syndrome. Autoimmun Rev 16: 1036-1043, 2017.","DOI":"10.1016\/j.autrev.2017.07.020"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22: 21-30, 2012.","DOI":"10.1007\/s10165-011-0571-z"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Erden A, Bolek EC, Yardimci KG, et al. Do ANCA-associated vasculitides and IgG4-related disease really overlap or not? Int J Rheum Dis 22: 1926-1932, 2019.","DOI":"10.1111\/1756-185X.13693"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Masuzawa N, Nishimura A, Mihara Y, et al. Clinicopathological analysis of ANCA-associated glomerulonephritis focusing on plasma cell infiltrate. Clin Exp Nephrol 23: 1373-1381, 2019.","DOI":"10.1007\/s10157-019-01785-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Thompson GE, Bourne MH Jr, Casal Moura M, et al. Pleuritis and pericarditis in antineutrophil cytoplasmic autoantibody-associated vasculitis. Chest 160: 572-581, 2021.","DOI":"10.1016\/j.chest.2021.02.049"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lega JC, Seror R, Fassier T, et al. Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. Semin Arthritis Rheum 43: 681-688, 2014.","DOI":"10.1016\/j.semarthrit.2013.09.001"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/1\/63_1040-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T03:28:53Z","timestamp":1704511733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/1\/63_1040-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1040-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"1040-22"}}